key: cord-0828396-514dfr5c
authors: Goyal, Alpesh; Gupta, Yashdeep; Kalaivani, Mani; A.Praveen, Pradeep; Ambekar, Samita; Tandon, Nikhil
title: SARS-CoV-2 seroprevalence in individuals with type 1 and type 2 diabetes compared to controls
date: 2021-12-14
journal: Endocr Pract
DOI: 10.1016/j.eprac.2021.12.009
sha: bce1a41c0f8c3e1365074b7c947ab12a0afa0ef5
doc_id: 828396
cord_uid: 514dfr5c

OBJECTIVE: Data for association between diabetes and SARS-CoV-2 susceptibility are conflicting. We aimed to evaluate this association using an analytical cross-sectional study design. METHODS: Study participants were recruited from endocrine clinics of our hospital and belonged to three groups: group 1 (T1DM), group 2 (T2DM), and group 3 (controls). All participants submitted blood samples for SARS-CoV-2 S1/S2 IgG antibody test (Diasorin Liaison), and were interviewed for history of documented infection. RESULTS: We evaluated total of 643 participants [T1DM: 149, T2DM: 160, Control: 334; mean age: 37.9±11.5 years]. A total of 324 (50.4%) participants were seropositive. Seropositivity rate was significantly higher in T1DM (55.7% vs. 44.9%, p=0.028) and T2DM (56.9% vs. 44.9%, p=0.013) groups, then control group. Antibody levels in seropositive T1DM and T2DM participants were not significantly different from seropositive controls. On multivariable analysis, low education status [OR: 1.41 (95% CI, 1.03, 1.94), p=0.035], diabetes [OR: 1.68 (95% CI, 1.20, 2.34), p=0.002], and overweight/obesity [OR: 1.52 (95% CI, 1.10, 2.10), p=0.012] showed significant association with SARS-CoV-2 seropositivity. The association between diabetes and SARS-CoV-2 seropositivity was found to further increase in participants with co-existing overweight/obesity [adjusted OR, 2.63 (95% CI, 1.54, 4.47, p<0.001]. CONCLUSIONS: SARS-CoV-2 seropositivity, assessed before the onset of national vaccination program, was significantly higher in participants with T1DM and T2DM, compared to controls. The antibody response did not differ between seropositive participants with and without diabetes. These findings point towards an increased SARS-CoV-2 susceptibility for patients with diabetes, in general, without any differential effect of the diabetes type.

available from the corresponding author on reasonable request. The coronavirus disease 2019 pandemic has affected lives globally for more than 110 a year now. At the time of writing this paper, >175.9 million confirmed cases and >3.8 million 111 fatalities have been reported worldwide [1] . Diabetes is estimated to affect 463 million adults, 112 representing 9.3% of the global adult population [2] . It is therefore not surprising that diabetes 113 (along with hypertension and obesity) has been commonly reported in COVID-19 patients. A 114 recent meta-analysis of 18 studies reported pooled prevalence of diabetes among patients with 115 COVID-19 as 11.5% (95 % CI, 9.5 to 13.4) [3] . Besides being a common comorbidity, diabetes 116 associates with an increased risk of severe disease [OR 2.35 diabetes and SARS-CoV-2 infection [12] . As many as seven undetected infected individuals 128 may exist in community for every single RT-PCR confirmed case [11] , and hence the findings 129 of latter study may not be generalisable to SARS-CoV-2 infection, as a whole. There are no Indirect evidence on the question of susceptibility can also be gathered by comparing 134 prevalence of diabetes in COVID-19 patients with that in the general population. 135 The estimates have varied from 7.2-27.3% in various studies from China, Italy, USA and India, 136 which are lesser, equal or greater than the background prevalence of diabetes in these 137 countries [13] [14] [15] [16] [17] [18] [19] [20] [21] . Therefore, based on these data, it is difficult to draw any firm conclusion 138 with regards to disease susceptibility. Besides, there are two major limitations in interpreting 139 these results as surrogates for diabetes susceptibility: a) there is a lack of clarity or 140 heterogeneity across studies in terms of how diabetes was defined as a comorbidity, and 141 b) these data are derived from patients admitted in hospital and/or intensive care units, and 142 therefore likely to be biased in terms of disease severity, and the presence of diabetes. A formal 143 study which evaluates and compares prior SARS-CoV-2 infection, both symptomatic and 144 asymptomatic, in persons with and without diabetes, defined using standard biochemical 145 criteria, is therefore needed to address this unanswered question.

With this background, we planned this analytical cross-sectional study to evaluate and 148 compare the seroprevalence of SARS-CoV-2 among individuals with (cases) and without 149 diabetes (controls) visiting our hospital, who were enrolled before the onset of national 

This was an analytical cross-sectional study conducted at a tertiary care center in North India.

The study was approved by the institutional ethics committee 110/05.02.2021, RP-40/2021).

This study included three groups: group 1 (T1DM), group 2 (T2DM), and group 3 (controls: 163 individuals without diabetes). All study participants submitted blood samples between 164 1 st October 2020 and 27 th February 2021, as a part of ongoing research projects. Participants in 165 groups 1 and 2 were recruited from general and/or specialty endocrine clinics run by the 166 department. Type 1 diabetes was defined according to the following clinical definition: a) age 167 at onset of diabetes less than 25 years, b) persistent insulin requirement within 6 months from 168 the diagnosis of diabetes, and c) absence of pancreatic calcification and features of insulin 169 resistance such as acanthosis nigricans. Presence of ketosis and pancreatic beta-cell 170 autoantibodies was used as an additional supportive feature. Type 2 diabetes was defined 171 according to the following clinical definition: a) variable age at onset, b) presence of obesity, 172 a positive family history, and features of insulin resistance such as acanthosis nigricans, c) lack 173 of insulin dependence for glycemic control, at least early in the disease course. We have an 174 ongoing study involving a cohort of women with hyperglycemia in pregnancy and a comparator 175 group of women with normoglycemia in pregnancy, who are followed-up in the postpartum 176 period, along with their spouses. These women and their spouses have been included as 177 controls in the present study after confirming that they presently do not have diabetes, i.e., 178 fasting plasma glucose (<126 mg/dl or 7.8 mmol/L), post 75 g glucose load 2-h-plasma glucose 179 (<200 mg/dl or 11.1 mmol/L) and HbA1c (<6.5% or 48 mmol/mol). The humoral immune response against SARS-CoV-2 S1/S2 spike proteins, measured in terms 367 of antibody levels, was comparable among seropositive individuals with and without diabetes.

These findings are in agreement with those reported in a study by Lampasona et diabetes. These women were exposed to hyperglycemia in the past, and remain at a high risk 420 of future diabetes, however, they did not meet the criteria for diabetes in the present assessment. 

Clinical characteristics and outcomes 479 of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-480 epicenter): A Nationwide Analysis of China

Analysis of Epidemiological and Clinical Features in Older 482 Patients with Coronavirus Disease 2019 (COVID-19) Outside Wuhan

Risk Factors Associated with Acute Respiratory Distress 485

Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China 486

Cardiovascular Implications of Fatal Outcomes of Patients 489 with Coronavirus Disease

Baseline Characteristics and Outcomes of 1591

Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy 493

Antibody response to multiple antigens of 496

SARS-CoV-2 in patients with diabetes: an observational cohort study

CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected 499

Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Clinical course and outcome of patients with 502 COVID-19 in Mumbai City: an observational study

Abbreviations: T1DM, type 1 diabetes; T2DM, type 2 diabetes 629 Data expressed as n, %, or median

Reference category includes: a) age <50 years, b) female gender, c) employed, d) education till graduate 660 and above, e) no diabetes, f) normal body mass index (<25 kg/m 2 ), g) normotensive, and h) no metabolic

Reference category includes: a) age <50 years, b) female gender, c) employed, d) education till graduate 678 and above, e) HbA1c <8% or 64 mmol/mol, f) normal body mass index (<25 kg/m 2 ), g) normotensive

metabolic syndrome, and i) duration of diabetes <10 years